ARCHIVES

Trifluridine and Tipiracil Hydrochloride Increase OS, PFS in Phase III Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 7 | July 25, 2014

Download PDF Visit The Full Archive

Related Articles

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

December 2, 1983

NIH Consensus Conference Agenda, Registration Online.

September 1, 2000

DCT Counselors Ponder Coordination, New Opportunities

December 12, 1975

Cancer Advocacy: March On Washington Scheduled For September 1998

October 31, 1997

NCI Takes Action Against Investigators Who Gave Drug Without An IND; M.D. Anderson Contract Canceled

August 28, 1981

Cranial Radiation Eliminated With Personalized Chemo

August 28, 2009